Mylan NV reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to the company’s emergency allergy shot EpiPen, which became the center of a firestorm over price increases.
Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Mylan reportedly let go between 200 and 300 people from its West Virginia operations.
Mylan NV raised the lower end of its 2017 forecasts as the U.S. drugmaker expects to benefit from the earlier-than-expected approval of its copycat of Teva’s blockbuster multiple sclerosis treatment Copaxone.
The prices of injectable cancer drugs – even older medicines around since the 1990s – are increasing at a rate far higher than inflation, researchers report in the Journal of Clinical Oncology.
The U.S. FDA announced measures designed to speed to market generic versions of complex drugs in an effort to address the rising costs of pharmaceuticals.
A U.S. regulator told Pfizer Inc.’s Meridian Medical Technologies division, maker of the EpiPen injector device, that serious component and product failures have been associated with patient deaths and severe illness.
Mylan NV finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment.